Across TCGA pan-cancer cohorts, APOM Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated APOM data layer compared with 24 for mass-spec protein and 8 for mass-spec protein.
The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher APOM Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated APOM expression acts as an unfavorable survival marker.
UCEC are the cancer types where APOM Mutation most reproducibly stratifies survival.